» Articles » PMID: 29020179

The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine

Overview
Journal Clin Infect Dis
Date 2017 Oct 12
PMID 29020179
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Antigenically drifted A(H3N2) viruses circulated extensively during the 2014-2015 influenza season. Vaccine effectiveness (VE) was low and not significant among outpatients but in a hospitalized population was 43%. At least one study paradoxically observed increased A(H3N2) infection among those vaccinated 3 consecutive years.

Methods: We followed a cohort of 1341 individuals from 340 households. VE against laboratory-confirmed influenza was estimated. Hemagglutination-inhibition and neuraminidase-inhibition antibody titers were determined in subjects ≥13 years.

Results: Influenza A(H3N2) was identified in 166 (12%) individuals and B(Yamagata) in 34 (2%). VE against A(H3N2) was -3% (95% confidence interval [CI]: -55%, 32%) and similarly ineffective between age groups; increased risk of infection was not observed among those vaccinated in 2 or 3 previous years. VE against influenza B(Yamagata) was 57% (95% CI: -3%, 82%) but only significantly protective in children <9 years (87% [95% CI: 43%, 97%]). Less than 20% of older children and adults had ≥4-fold antibody titer rise against influenza A(H3N2) and B antigens following vaccination; responses were surprisingly similar for antigens included in the vaccine and those similar to circulating viruses. Antibody against A/Hong Kong/4801/14, similar to circulating 2014-2015 A(H3N2) viruses and included in the 2016-2017 vaccine, did not significantly predict protection.

Conclusions: Absence of VE against A(H3N2) was consistent with circulation of antigenically drifted viruses; however, generally limited antibody response following vaccination is concerning even in the context of antigenic mismatch. Although 2014-2015 vaccines were not effective in preventing A(H3N2) infection, no increased susceptibility was detected among the repeatedly vaccinated.

Citing Articles

Delay of innate immune responses following influenza B virus infection affects the development of a robust antibody response in ferrets.

Rowe T, Fletcher A, Lange M, Hatta Y, Jasso G, Wentworth D mBio. 2025; 16(2):e0236124.

PMID: 39772665 PMC: 11796412. DOI: 10.1128/mbio.02361-24.


Interferon as an immunoadjuvant to enhance antibodies following influenza B infection and vaccination in ferrets.

Rowe T, Fletcher A, Svoboda P, Pohl J, Hatta Y, Jasso G NPJ Vaccines. 2024; 9(1):199.

PMID: 39448628 PMC: 11502657. DOI: 10.1038/s41541-024-00973-2.


Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.

Rowe T, Davis W, Wentworth D, Ross T J Virol. 2024; 98(2):e0149423.

PMID: 38294251 PMC: 10878268. DOI: 10.1128/jvi.01494-23.


Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection.

Voronina D, Shcheblyakov D, Favorskaya I, Esmagambetov I, Dzharullaeva A, Tukhvatulin A Viruses. 2022; 14(11).

PMID: 36366583 PMC: 9698552. DOI: 10.3390/v14112485.


Antiviral Peptides as Anti-Influenza Agents.

Agamennone M, Fantacuzzi M, Vivenzio G, Scala M, Campiglia P, Superti F Int J Mol Sci. 2022; 23(19).

PMID: 36232735 PMC: 9569631. DOI: 10.3390/ijms231911433.


References
1.
Belongia E, Simpson M, King J, Sundaram M, Kelley N, Osterholm M . Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016; 16(8):942-51. DOI: 10.1016/S1473-3099(16)00129-8. View

2.
Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath J . Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016; 21(7):pii=30139. DOI: 10.2807/1560-7917.ES.2016.21.7.30139. View

3.
Ohmit S, Petrie J, Cross R, Johnson E, Monto A . Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011; 204(12):1879-85. DOI: 10.1093/infdis/jir661. View

4.
Appiah G, Blanton L, DMello T, Kniss K, Smith S, Mustaquim D . Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2015; 64(21):583-90. PMC: 4584770. View

5.
Monto A, Petrie J, Cross R, Johnson E, Liu M, Zhong W . Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J Infect Dis. 2015; 212(8):1191-9. DOI: 10.1093/infdis/jiv195. View